Jeena Sikho Lifecare Limited — Investor Meet, 18-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Jeena Sikho Lifecare Limited reported significant growth in H1 FY25 with a revenue of INR 214 crores, marking a 36% increase year-on-year. The hospital services segment led this surge, growing by 72% to INR 114 crores, while product sales increased by 10% to INR 100 crores. EBITDA also saw a robust growth of 32% to INR 59.28 crores with an EBITDA margin of 28%. PAT rose by 47% to INR 46.88 crores, reflecting a strong enhancement in profit margins.

2. Future Outlook and Growth Drivers: Management underscored ambitious expansion plans, targeting an operational capacity of 2,100 beds by March 2025. The introduction of new products into the OTC market is anticipated, capitalizing on favorable market conditions and increasing demand for Ayurvedic solutions. Management projects a target revenue of INR 650-700 crores by FY26, with plans to penetrate international markets.

3. Order Book and Operational Updates: The company is expanding vigorously, managing 1,530 operational beds and planning to add 600 beds across various locations in India. The occupancy rate has improved to approximately 51%, up from 38% last year.

4. Analyst Q&A Insights (Detailed):

• Revenue and Profitability: Analysts sought clarity on revenue distribution across hospitals, confirming the top locations driving sales, and management highlighted diversified contributions across cities.

• Market Position and Competitive Landscape: Management noted 80% of their patients come after pursuing allopathic treatments, suggesting significant market potential in addressing dissatisfaction with conventional medicine.

• Operational Challenges or Risks: Management acknowledged increasing regulatory developments, especially regarding cashless treatments, which could influence patient inflow and company revenues.

• Capex and Capital Allocation: Capex remains controlled, with management focused on acquiring hospital operations rather than making high upfront investments.

• Strategic Priorities and Long-Term Vision: Management reiterated a focus on bed expansion, maintaining sustainable growth without compromising quality or accessibility.

5. Market or Regulatory Updates: The recent Supreme Court order to include Ayurveda under the Ayushman Yojana could provide substantial business opportunities, enhancing patient access to Ayurvedic treatments through government plans.

6. Strategic Focus Areas: The management's emphasis on organic growth, innovative product developments, and patient-centric approaches suggest a robust strategic roadmap aimed at long-term sustainability and competitive advantage.

7. Investor Insight: The financial health and growth trajectory appear favorable, aligning with a cautious ‘buy’ stance due to strong revenue growth, expanding operational capacity, and promising market dynamics without significant preceding risks.